Hiddo Lambers Heerspink is Professor of Clinical Trials and Personalized Medicine and a clinical trialist at the Department of Clinical Pharmacy and Pharmacology at the University Medical Center Groningen and visiting professor at the University of New South Wales in Sydney. He studied pharmacy at the University of Groningen and received his PhD from the University Medical Center Groningen.
Professor Lambers Heerspink’s research interests focus on optimizing current treatment strategies and finding new therapeutic approaches to halt the progression of renal and cardiovascular diseases in patients with chronic kidney disease with a specific focus on personalized medicine. He leads numerous clinical trials with new interventions to reduce kidney and cardiovascular complications of chronic kidney disease. His main expertise includes clinical trial design, personalized medicine as well as methodological aspects and statistical analyses of clinical trials.
Professor L. Heerspink has authored and co-authored over 350 peer-reviewed publications and is editorial board member of Diabetes Obesity and Metabolism and the Clinical Journal of the American Society of Nephrology. Prof L. Heerspink is a consultant and has received honoraria from AbbVie, AstraZeneca, Boehringer Ingelheim, CSL Pharma, Janssen, Fresenius, Gilead Sciences, Merck, Mitsubishi Tanabe, Mundi Pharma and Retrophin.